Arrowhead Pharmaceuticals Inc. (ARWR) is gearing up for another turning point as it hit the volume of 1.58

A new trading day began on Friday, with Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) stock price up 32.56% from the previous day of trading, before settling in for the closing price of $55.15. ARWR’s price has ranged from $20.67 to $42.48 over the past 52 weeks.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

During the last 5-year period, the sales growth of Healthcare Sector giant was 205.96%. Meanwhile, its annual earnings per share averaged -40.82%. With a float of $116.45 million, this company’s outstanding shares have now reached $123.90 million.

Arrowhead Pharmaceuticals Inc. (ARWR) Insider Activity

As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Arrowhead Pharmaceuticals Inc. is 6.01%, while institutional ownership is 61.34%. The most recent insider transaction that took place on Jan 31, was worth 1,860,019. In this transaction Chief Executive Officer of this company sold 57,499 shares at a rate of $32.35, taking the stock ownership to the 3,715,048 shares. Before that another transaction happened on Jan 12, when Company’s Chief Discovery/Trans Medicine sold 7,940 for $36.89, making the entire transaction worth $292,904. This insider now owns 210,851 shares in total.

Arrowhead Pharmaceuticals Inc. (ARWR) Earnings and Forecasts

In its latest quarterly report, released on 12/30/2023, the company reported earnings of -$1.24 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.65 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -40.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.33% during the next five years compared to -24.19% drop over the previous five years of trading.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Trading Performance Indicators

Here are Arrowhead Pharmaceuticals Inc.’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 22.20.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.77, a number that is poised to hit -0.48 in the next quarter and is forecasted to reach -2.48 in one year’s time.

Technical Analysis of Arrowhead Pharmaceuticals Inc. (ARWR)

Looking closely at Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), its last 5-days average volume was 1.7 million, which is a drop from its year-to-date volume of 1.8 million. As of the previous 9 days, the stock’s Stochastic %D was 44.38%. Additionally, its Average True Range was 1.91.

During the past 100 days, Arrowhead Pharmaceuticals Inc.’s (ARWR) raw stochastic average was set at 62.06%, which indicates a significant increase from 56.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.42% in the past 14 days, which was lower than the 77.59% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $30.91, while its 200-day Moving Average is $31.16. However, in the short run, Arrowhead Pharmaceuticals Inc.’s stock first resistance to watch stands at $33.28. Second resistance stands at $34.01. The third major resistance level sits at $35.34. If the price goes on to break the first support level at $31.23, it is likely to go to the next support level at $29.90. Should the price break the second support level, the third support level stands at $29.17.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Key Stats

With a market capitalization of 4.03 billion, the company has a total of 123,897K Shares Outstanding. Currently, annual sales are 240,740 K while annual income is -205,280 K. The company’s previous quarter sales were 16,100 K while its latest quarter income was -109,680 K.